Send your comments and tips to whitecoat@globe.com
  Awards Beth Israel Deaconess Medical Ctr. Boston Medical Center Boston University Brigham and Women's Hospital Broad Institute Cambridge Health Alliance Caritas St. Elizabeth's Medical Ctr. Children's Hospital Boston Dana-Farber Cancer Institute Grants Harvard University Joslin Diabetes Center Lahey Clinic Mass. General Hospital Mass. Health Law McLean Hospital MIT New England Baptist Hospital Personnel Moves Public Health Research Short White Coat Tufts-New England Medical Center Tufts University UMass Memorial Medical Center University of Massachusetts VA Medical Centers    A Healthy Blog Running A Hospital Nature Network Boston SciBos - Corie Lok's blog Kevin, M.D. Blog, MD Nurse at small Dr. Gwenn Is In Healthy Children blog WBUR's CommonHealth Other Globe Blogs
Elizabeth Cooney is a health reporter for the Worcester Telegram &
Gazette.
Boston Globe Health and Science staff:
Scott Allen Alice Dembner Carey Goldberg Liz Kowalczyk Stephen Smith Colin Nickerson Beth Daley Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor. Short White Coat blogger Ishani Ganguli Short White Coat blogger Jennifer Srygley  Week of:
November 11
Week of:
November 4
Week of:
October 28
Week of:
October 21
Week of:
October 14
Week of:
October 7
|
« The revolution will be e-mailed | Main | Houston $3b, Boston $1b » Thursday, June 14, 2007Today's Globe: DNA challenge, aging workers, diet pillA massive international study of the human genome has caused scientists to rethink some of the most basic concepts of cellular function. Genes, it turns out, may be relatively minor players in genetic processes that are far more subtle and complicated than previously imagined. An aging workforce, combined with the growing obesity epidemic and the high cost of medical care, could result in an epidemic of preventable illness that might cripple the region's economy, according to a study being released this morning by the New England Health Care Institute and the Boston Foundation. Sanofi-Aventis SA's weight loss pill Acomplia shouldn't be approved in the United States because the company hasn't showed that the benefits outweigh the risk of suicidal thoughts among those taking the drug, an advisory panel said. Posted by Elizabeth Cooney at 06:34 AM
|
